LONDON
Wed Mar 31, 2010 7:43pm EDT
(Reporting by Ben Hirschler)
(Reuters) - Eli Lilly's lung cancer drug Alimta has been recommended for use on Britain's state health service as a maintenance treatment, after a change of heart by the national health cost board.
The National Institute for Health and Clinical Excellence (NICE) -- which backed Alimta, or pemetrexed, as a first-line treatment for non-small-cell lung cancer in September -- had said in December that...
Clarient Insight(R) Dx Pulmotype(R) Test Aids Physicians in Classifying Subtypes of Lung Cancer, Identifying Most Effective Therapy
ALISO VIEJO, Calif., Feb. 10 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer...
IntrinsiQ Study: Oncologists Overlook Maintenance Therapy Option – More Often than They Realize
Surprise Findings from First IntelliView 360™ Research Reveal Underserved Cancer Patient Population
September 15, 2009 10:00 AM Eastern Daylight Time
WALTHAM, Mass.--(BUSINESS WIRE)--IntrinsiQ, the company improving the quality and understanding of cancer care, today announced the findings of the company’s first IntelliView 360™ research study. The biggest...
The U.S. Food and Drug Administration has approved Alimta (pemetrexed), the first drug available for maintenance therapy of advanced or metastatic lung cancer.
Patients with cancer often receive maintenance therapy to prevent the disease from progressing after their tumor has shrunk or the disease has stabilized in response to chemotherapy. Alimta disrupts metabolic processes that are dependent on the B-vitamin...
Pemetrexed Improves Overall Survival in Patients With Advanced Non-Small-Cell Lung Cancer: Presented at ASCO
By Emma Hitt, PhD
ORLANDO, Fla -- June 1, 2009 -- Pemetrexed maintenance therapy improves overall survival (OS) and progression-free survival (PFS), compared with placebo, in patients with advanced non-small-cell lung cancer (NSCLC), according to results of a phase 3 trial presented here at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO)....
